Skin rejuvenation with Celora Vita

As regenerative aesthetic medicine continues to evolve, there is increasing interest in treatments that support the skin’s biological environment. Celora Vita is a newly introduced injectable biorestorative treatment developed to provide substrate support through a combination of a targeted amino-acid complex and low-molecular-weight hyaluronic acid (LMWHA).

This case study reflects an exploratory clinical use of the product in practice. As a newly launched treatment, the objective was not only to improve skin quality, but also to better understand the visible changes that could be achieved through this biological-led approach alone.

Patient profile
The patient was a 42-year-old female with Fitzpatrick Skin Type II. Her primary concerns were dehydration and mild pigmentation, alongside a generally dull skin appearance. Clinically, baseline skin ageing changes were mild and there was no relevant medical history or contraindication to treatment.

Importantly, the patient had previously completed a course of Polynucleotides HPT (Plinest) approximately five to six months earlier. This made her a particularly suitable candidate for Celora Vita, which was selected to support the skin following fibroblast proliferation and activation induced by Polynucleotides HPT. The case also provided an opportunity to evaluate the visible skin quality changes that could be achieved through a substrate-based approach.

Treatment rationale
Celora Vita combines a targeted amino acid complex with LMWHA to support fibroblast metabolism, complete extracellular matrix synthesis and overall skin quality. The treatment rationale in this case centred on providing the skin with substrates relevant to collagen production and tissue repair following previous fibroblast activation.

Structural amino acids such as glycine, proline and lysine are fundamental to collagen synthesis and matrix stability, while branched-chain amino acids including leucine, valine and isoleucine are involved in cellular protein synthesis and fibroblast activity through pathways including mTOR signalling. Ageing and environmentally stressed skin may demonstrate reduced efficiency in extracellular matrix renewal, even where viable fibroblasts remain present. Providing relevant substrates may therefore help support regenerative processes and dermal remodelling.

The inclusion of LMWHA was expected to support hydration and dermal signalling, while the amino acid component was ntended to optimise the metabolic environment for collagen synthesis and skin regeneration.

At the outset, hydration improvement was the primary anticipated outcome. However, as this represented an early clinical experience with the product, broader changes in pigmentation, redness and overall dermal appearance were considered exploratory observations rather than predefined expectations.

Treatment protocol
The patient underwent a course of three Celora Vita treatment sessions between November 2025 and February 2026.

Treatments were performed on:

• 27 November 2025
• 18 December 2025
• 2 February 2026

A superficial multi-puncture injection technique was used with a needle, following a similar approach to standard polynucleotide delivery protocols. The product was placed superficially within the dermis to achieve even distribution across the treatment area.

One full 5mL vial of Celora Vita was administered at each session. No additional injectable or device-based treatments were performed during the treatment period in order to better evaluate the isolated effects of the product.

Standard pre-treatment preparation included topical anaesthetic application to improve patient comfort during injection. Mild transient papules were observed immediately post-procedure, consistent with superficial intradermal placement, with resolution occurring within a few days.

Clinical outcomes
Before-and-after assessment photographs taken between 27 November 2025 and 10 February 2026 demonstrated progressive improvements in multiple aspects of skin quality across the  treatment course.

The earliest and most noticeable change was an improvement in skin hydration, with the patient reporting that the skin both looked and felt more hydrated following treatment. As sessions progressed, additional visible improvements became apparent, including reductions in mild pigmentation and skin redness, alongside a more even and refreshed overall skin appearance.


These findings are consistent with the proposed role of amino acid and hyaluronic acid-based biorestorative approaches in supporting extracellular matrix function and visible rejuvenation without volumisation.

Clinical improvements appeared to develop progressively throughout the treatment course, with continued enhancement visible on final assessment of photography following the third session.

Patient experience and tolerability The patient reported a positive overall treatment experience and was satisfied with the final outcome achieved following the treatment course. Downtime was minimal and primarily consisted of temporary papules immediately following injection, alongside some minor bruising. These effects resolved within a few days and did not significantly impact normal daily activities. Appropriate pre-treatment topical anaesthesia helped improve overall comfort during the procedure.

Positioning Celora Vita in clinical practice
This case highlights the valuable role of Celora Vita as a substrate-based biorestorative treatment within regenerative aesthetic practice. The treatment is positioned as a substratebased approach to skin rejuvenation, designed to support dermal function and extracellular matrix renewal.

The treatment may be appropriate for a broad range of patients seeking improvements in skin quality, hydration and overall dermal function, including those with early or mild signs of skin ageing. It may also have value both as a standalone regenerative treatment and as part of a broader treatment plan incorporating fibroblast-stimulating procedures.

In this case, Celora Vita was used following a previous course of Polynucleotides HPT, based on the principle that activated fibroblasts first may then benefit from additional substrate availability during regenerative processes. A potential treatment strategy within clinical practice may therefore involve alternating Celora Vita with fibroblast-stimulating treatments such as Polynucleotides HPT every couple of weeks to support ongoing extracellular matrix remodelling and tissue repair. The product may also integrate well alongside other collagen-stimulating procedures, where optimisation of the biological environment may help support treatment outcomes and skin quality improvements.

Final reflections
This case provided an early insight into the potential role of substrate-based biorestoration within regenerative aesthetic medicine. While hydration improvement was the most anticipated outcome at the outset, progressive enhancements were also observed in pigmentation, redness and overall skin quality across the treatment course.

The case additionally demonstrated how Celora Vita may integrate within broader regenerative treatment strategies, particularly following fibroblast-stimulating procedures such as Polynucleotides HPT.

Although further clinical evaluation is needed, this early experience suggests that substrate support may represent an important consideration within regenerative treatment planning, particularly as aesthetic medicine continues to move towards more biology-led approaches to skin rejuvenation.


Dr Xavier is an experienced practitioner, regularly training surgeons, doctors, and other medical practitioners in a range of medical aesthetic procedures and is a lead trainer for a number of pharmaceutical companies.

References: 1. Scarano A, et al. Evaluation of skin quality improvement following injectable amino acid and hyaluronic acid treatment. Clin Cosmet Investig Dermatol. 2. Svolacchia F, et al. Amino acid-based injectable therapies for skin rejuvenation and extracellular matrix support. Dermatol Ther. 3. De Servi B, et al. Hyaluronic acid fragments and amino acid complexes in skin biorevitalisation: mechanisms and clinical applications. J Cosmet Dermatol. 4. Cavallini M, et al. Polynucleotides in regenerative aesthetic medicine: mechanisms and clinical applications. Aesthetic Medicine. 5. Kim J, et al. Fibroblast activation and extracellular matrix remodelling following regenerative injectable treatments. J Drugs Dermatol. 6. Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929-958. 7. Wu G. Amino acids: metabolism, functions and nutrition. Amino Acids. 2009;37(1):1-17. 8. Kimball SR, Jefferson LS. Signalling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr. 2006;136(1 Suppl):227S-231S. 9. Solano López GE, et al. Injectable biorestorative therapies and skin quality outcomes: current evidence and clinical perspectives. J Clin Aesthet Dermatol.